Haier Biomedical: Contribute Scientific and Technological Advances to Global Biosafety

Lets’ take a look at Haier Biomedical while at the China International Import Expo from an international perspective: contributing scientific and technological advances to global biosafety

From November 5 to 10, 2020, the highly anticipated 3rd China International Import Expo (hereinafter referred to as the “Import Expo”) was held at Shanghai National Exhibition and Convention Center. Exhibitors from all over the world gathered together to compete, exchange, and discuss with each other their latest technologies, which has injected new impetus into the world's economic growth. Haite Biomedical, an overseas subsidiary of Haier Biomedical (the IoT biosafety brand under Yingkang Life), made its debut at the Import Expo and intensively demonstrated its innovative full-scenario IoT biosafety solutions, covering bio-sample safety, blood safety, vaccine safety, drug safety and laboratory safety.

From an international perspective, Haier Biomedical has transformation from high-end brand to solution-based brand and then to ecosystem brand by focusing on the IoT science and technology ecosystem strategy, with the creation of independent innovations and disrupting the once foreign monopolies in the biomedical sector. Now, it has become the world's leading provider of IoT biosafety solutions and gradually introduced the basis of IoT biosafety technology from the domestic market to global markets, continuously contributing scientific and technological forces to global biosafety.

The ecosystem-based global dual-wheel driving strategy continues to be upgraded

Haier Biomedical has further brought its new technologies and new concepts to the world at the Import Expo. In fact, long before the event, Haier Biomedical’s innovative IoT solutions have been distributed to the world.

Taking the vaccine network as an example, in the process of "global coverage", Haier Biomedical has widely replicated its scientific and technological ecosystem model to Ethiopia, Uzbekistan and other countries. Also, it has created the Sunshine Vaccination Ecosystem jointly with the United Nations Children's Fund (UNICEF), the World Health Organization, GAVI the Global Alliance for Vaccines and Immunization and other related institutions, entering 78 countries and regions along the "Belt and Road" and guarding the health of over 200 million children around the world. It has lived up to the slogan “wherever the sun goes, there a vaccine”. According to statistics, Haier Biomedical, as a long-term procurement contract supplier of cold chain vaccines equipment for UNICEF, has achieved a market share of nearly 30% for three consecutive years.

At the Import Expo, Haier Biomedical also reached strategic cooperation on "smart management and service of vaccines" with Sanofi Pasteur, a leading century-old French vaccine manufacturer. According to the agreement, the two parties will build a high-quality and efficient smart vaccination ecosystem together relying on the application of the Internet of Things + digital technologies in the field of vaccine management to promote the construction of intelligent vaccine management and service models to constantly meet the public's higher requirements, demands and expectations for safe, secure and assured vaccines.  

Apart from vaccines expansion, Haier Biomedical has also successfully completed projects in the United States, the United Kingdom, Germany, the Netherlands, Denmark and other developed countries in terms of biological sample scenario solutions. In 2019, Haier Biomedical beat traditional European and American enterprises and won the bid for Denmark's public health procurement with its ultra-low temperature sample network solutions. From "going out" to "going in" and then to "going up", Haier Biomedical has been constantly increasing product share in the high-end markets across the world and has gained a firm foothold in the international market.

A truly leading independent technology needs no hype or to showoff, the market will give the recognition it deserves. According to the latest data released in the third-quarter report, Haier Biomedical has maintained rapid growth in overseas markets in the first three quarters, with a year-on-year growth of 86.83% in revenue. Among this, overseas distribution revenue has increased by 67.00% and overseas project revenue has increased by 128.71% on a year-on-year basis. In terms of overseas distribution, the company has been strengthening the construction of the overseas distribution network system and constantly increasing its brand influence across the globe. In terms of overseas projects, the company has won bids for the national immunization project in Myanmar, the center for disease control and prevention project in South Sudan, and the national immunization project in Cameroon as key examples. The dual-wheel drive strategy has effectively guaranteed the sustainable development of the company’s international business.

Global-leading independent technologies help the company to seize and maintain its commanding growth in biomedical technology

Relying on its global-leading independent technologies, Haier Biomedical has secured full cooperation with many world-famous enterprises and has constantly expanded its Internet of Things science and technology ecosystem layout, becoming a new force in the construction of global biosafety.

In earlier years, as the biotechnology infrastructure was weak in China, low-temperature and cold chain equipment needed to be imported in large quantities. In this regard, Haier Biomedical took the lead in the industry and developed China's first cryogenic refrigerator and ultra-low temperature refrigerator through independent innovations and broke through the international monopolies to achieve import substitution.

On October 30, 2020, upon appraisal of more than 10 experts, including Academician Wang Jun and President Gu Zhen, Haier Biomedical’s four scientific achievements, respectively as follows the “IoT smart blood management system based on electronic blood matching and RFID technology, smart vaccine management system based on Internet of Things technology, development of dual-system air-cooled -30℃ cryogenic incubator, application of the key technology of air flow field design in biosafety cabinets” were all rated simultaneously as international leading products and solutions. On the racing track of biosafety, Haier Biomedical has constantly been rising in the sector as the leader and continues to reach commanding heights of biomedical technology by promoting the need for ongoing upgrades of the public health and biosafety industries.

From being enslaved to others to now being the international leader in the biomedical sector, Haier Biomedical has become a global leading enterprise in bio-medical cryogenic storage and has transformed into the leading provider of IoT biosafety solutions. Up to now, Haier Biomedical has a total of 288 patents and 34 American Energy Star certifications and has led or participated in the drafting of 9 national and industrial standards and 1 WHO international standard. We have basically covered all biomedical cryogenic storage products and promoted the need for continuous development and investment in the industry.

The development of new technological products lies in continuous innovations, and without innovation solutions will eventually become redundant. Therefore, Haier Biomedical leads the industry to move towards the ecosystem and injects scientific and technological forces into the world through continuous innovations and investment in products and solutions to meet the growing need of all. It is foreseeable, under such a development trend, Haier Biomedical will continue to gain through investment and hard work and increase in the global market.